Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoproliferative Disorders 6Hematologic Diseases 6Immunoproliferative Disorders 5Lymphoma, Non-Hodgkin 4Lymphatic Diseases 4Multiple Myeloma 3Lymphoma 3Vascular Diseases 2Paraproteinemias 2Lymphoma, Large B-Cell, Diffuse 2Hemostatic Disorders 2Hemorrhagic Disorders 2Blood Coagulation Disorders 2Neoplasms, Plasma Cell 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1

Interventions

Rituximab 187Cyclophosphamide 174Etoposide 94Peripheral Blood Stem Cell Transplantation 90Vincristine 89Prednisone 80Doxorubicin 79Filgrastim 75fludarabine phosphate 60Radiotherapy 56Mycophenolic Acid 41Melphalan 41Cytarabine 41Busulfan 40Cyclosporine 39Methotrexate 37Whole-Body Irradiation 36Tacrolimus 35Carmustine 34Ifosfamide 28Lenalidomide 27Granulocyte Colony-Stimulating Factor 27Antilymphocyte Serum 27Gemcitabine 25Carboplatin 25Methylprednisolone 24ibritumomab tiuxetan 23Bortezomib 22Dexamethasone 21ibrutinib 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Lymphoma, Large B-Cell, Diffuse × dacetuzumab × Clear all
NCT00435916 2015-01-07

Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma

Seagen Inc.

Phase 2 Completed
46 enrolled
Lymphoid

Hematologic Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Lymphoma, Large B-Cell, Diffuse

NCT00655837 2014-12-18

Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL

Seagen Inc.

Phase 1 Completed
33 enrolled
Lymphoid

Hematologic Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡